ExThera Medical Corporation is developing revolutionary medical devices that address unmet clinical needs for the treatment of bloodstream infections and pathogen-reduction.

Based in Martinez, California with an office in the Netherlands, ExThera Medical Corporation is a privately held medical device company developing innovative, single-use blood filters capable of capturing a broad range of bacteria, viruses, parasites, toxins and other sepsis mediators.

ExThera was formed in 2007 through a joint venture between the Emergence Venture Partners Life Science Incubator and ExThera AB, at the Karolinska Institute of Stockholm. The company’s first product, the Seraph® 100 Microbind® Affinity Blood Filter, is CE Marked and commercially available in Europe.

The company is focused is on therapeutic applications to treat drug-resistant and drug-susceptible bloodstream infections in high-risk patient populations, with field deployable versions for biodefense and military use. ExThera also intends to develop, oncology, cardiovascular and diagnostic applications of its technology.



Bloodstream infections are a global health issue and are increasing in incidence despite significant efforts to find effective treatments. If not identified and treated early, these infections can cause serious illness by progressing to sepsis and septic shock with organ damage or organ failure and death.


757 Arnold Drive Suite B, Martinez,
× × × × × × ×


Why use this device on COVID 19 patients?
Seraph 100 binds SARS-CoV-2 and removes it from the blood. It has been shown to also remove inflammatory markers such as IL-6. Other inflammatory markers that have correlated to poor outcome such as d-dimers and Ferritin have decreased during and after treatment. Stabilization of blood pressure has also been reported and reduction in the need for vasopressors. This allows additional time for supportive care while reducing the source of inflammation and preventing further damage caused by the pathogen.

Are there additional applications for this device?
Seraph 100 has broad applications for the safe reduction of drug-susceptible and drug-resistant pathogens that are in the bloodstream. Secondary infections from other sources are a known complication of COVID-19.

How does it work?
Seraph 100 is a broad spectrum, anti-thrombogenic hemoperfusion device. Please watch the animation about how it works:


How do I use the device?
The Seraph 100 has standard luer lock fittings and be used with most standard blood pumps or hemofiltration devices at a blood flow rate ranging from 100-350 mL/min. Please consult the Instructions for Use for additional details.

Users in Europe
Please read the information sheet to learn more about the device and how to order it.

Users in United States
Please read the information sheet to learn more about the device and how to order it.
For FDA guidance on the use of Seraph 100 on COVID-19 patients, please follow the links below:

Find ExThera Medical in Social Media